Medical hopes bring biggest gains of week

The York-based company could soon be helping to ease the pain of thousands of Americans with chronic wounds.

Tissue Regenix has signed a deal which will help it to provide hope to people who believed they were facing a lifetime of discomfort.

The company has taken a step forward with its US commercialisation strategy by securing a major partnership.

It has signed a processing partnership with Community Tissue Services, which is one of the largest tissue banks in the US.

Community Tissue Services distributes more than 230,000 grafts for transplant annually.

Under the terms of the partnership, Community Tissue Services will use Tissue Regenix’s patented dCELL technology to produce human biological scaffolds, initially for use in acute and chronic wound care.

In the longer term, the range of uses will be expanded to cover other areas of clinical need.

Tissue Regenix’s dCELL dermis works by taking human donor skin and removing the DNA and cells, using the dCELL process to leave a dermis matrix that can be placed over the wound.

It can aid natural healing by attracting the patient’s own cells to the wound area.

Recently completed trials in the UK with NHS Blood and Transplant have shown that patients who have had chronic wounds for four-and-a-half years, who were treated with Tissue Regenix dCELL Dermis have seen an 87 per cent reduction in the size of all wounds, while 60 per cent of patients were completely healed.